Breaking News

Valeant’s Tampa Facility Receives FDA VAI Classification

Following collaboration with FDA, issues related to a cGMP inspection are being resolved

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Valeant Pharmaceuticals received confirmation from the FDA that it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, FL as part of a forthcoming Establishment Inspection Record for the facility. With this confirmation, manufacturing uncertainties related to current and upcoming regulatory submissions will be eliminated for products manufactured at the Tampa facility. “Following continued close collabor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters